500 related articles for article (PubMed ID: 10722564)
1. Role of toxin functional domains in anthrax pathogenesis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft SC; Weiss AA
Clin Vaccine Immunol; 2008 Jan; 15(1):71-5. PubMed ID: 18032590
[TBL] [Abstract][Full Text] [Related]
3. Anthrax toxin.
Bhatnagar R; Batra S
Crit Rev Microbiol; 2001; 27(3):167-200. PubMed ID: 11596878
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity induced by Bacillus anthracis toxin-deficient strains.
Pezard C; Weber M; Sirard JC; Berche P; Mock M
Infect Immun; 1995 Apr; 63(4):1369-72. PubMed ID: 7890396
[TBL] [Abstract][Full Text] [Related]
5. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
6. Toxins of Bacillus anthracis.
Brossier F; Mock M
Toxicon; 2001 Nov; 39(11):1747-55. PubMed ID: 11595637
[TBL] [Abstract][Full Text] [Related]
7. The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.
Brenneman KE; Doganay M; Akmal A; Goldman S; Galloway DR; Mateczun AJ; Cross AS; Baillie LW
FEMS Immunol Med Microbiol; 2011 Jul; 62(2):164-72. PubMed ID: 21401726
[TBL] [Abstract][Full Text] [Related]
8. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.
Nguyen ML; Terzyan S; Ballard JD; James JA; Farris AD
Infect Immun; 2009 Nov; 77(11):4714-23. PubMed ID: 19720758
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
Albrecht MT; Li H; Williamson ED; LeButt CS; Flick-Smith HC; Quinn CP; Westra H; Galloway D; Mateczun A; Goldman S; Groen H; Baillie LW
Infect Immun; 2007 Nov; 75(11):5425-33. PubMed ID: 17646360
[TBL] [Abstract][Full Text] [Related]
10. A new triple chimeric protein as a high immunogenic antigen against anthrax toxins: theoretical and experimental analyses.
Abdous M; Hasannia S; Salmanian AH; Shahryar Arab S; Shali A; Alizadeh GA; Hajizadeh A; Khafri A; Mohseni A
Immunopharmacol Immunotoxicol; 2019 Feb; 41(1):25-31. PubMed ID: 30621469
[No Abstract] [Full Text] [Related]
11. [Anthrax toxins].
Brossier F; Guidi-Rontani C; Mock M
C R Seances Soc Biol Fil; 1998; 192(3):437-44. PubMed ID: 9759382
[TBL] [Abstract][Full Text] [Related]
12. A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.
Chitlaru T; Israeli M; Rotem S; Elia U; Bar-Haim E; Ehrlich S; Cohen O; Shafferman A
Vaccine; 2017 Oct; 35(44):6030-6040. PubMed ID: 28342664
[TBL] [Abstract][Full Text] [Related]
13. Contribution of individual toxin components to virulence of Bacillus anthracis.
Pezard C; Berche P; Mock M
Infect Immun; 1991 Oct; 59(10):3472-7. PubMed ID: 1910002
[TBL] [Abstract][Full Text] [Related]
14. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection.
Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB
J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858
[TBL] [Abstract][Full Text] [Related]
15. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
16. Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Panchal RG; Halverson KM; Ribot W; Lane D; Kenny T; Abshire TG; Ezzell JW; Hoover TA; Powell B; Little S; Kasianowicz JJ; Bavari S
J Biol Chem; 2005 Mar; 280(11):10834-9. PubMed ID: 15644338
[TBL] [Abstract][Full Text] [Related]
17. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice].
Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C
Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel multiepitope chimeric vaccine against anthrax.
Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
[TBL] [Abstract][Full Text] [Related]
19. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
Wu G; Feng C; Cao S; Guo A; Liu Z
Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
[TBL] [Abstract][Full Text] [Related]
20. Revisiting the Concept of Targeting Only Bacillus anthracis Toxins as a Treatment for Anthrax.
Glinert I; Bar-David E; Sittner A; Weiss S; Schlomovitz J; Ben-Shmuel A; Mechaly A; Altboum Z; Kobiler D; Levy H
Antimicrob Agents Chemother; 2016 Aug; 60(8):4878-85. PubMed ID: 27270276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
